

Product	Beacon GC T30
Country	Germany
Manufacturing license No.	DE_RP_01_MIA_2022_0054
Potency	Δ^9 -Tetrahydrocannabinol approx. 30% Cannabidiol \leq 1%
Dosage form	Cannabis Flowers, dried; cultivar: Garlic Cookies
Pack size	10 g PE/PP-Container
Batch	26401

Bulk manufacturer	Natural MedCo Ltd. 2941 Napperton Drive, Strathroy / Ontario N7G3H8 - Canada	
Packager	PS Pharma Service GmbH Lise-Meitner-Str. 10 40670 Meerbusch	Manufacturing Date: 23.07.2024
Manufacturing license No.:	DE_NW_03_MIA_2024_0022	

Test	Method	Specification	Result	Complies
Odour	Organoleptic	Characteristic of cannabis flowers	Complies	YES
Identification A	DAB Monograph	Complies with the description of the DAB monograph	Complies	YES
Identification B	DAB Monograph	Complies with the description of the DAB monograph	Complies	YES
Identification C	DAB Monograph (TLC) EP 2.2.27	Complies with the description of the DAB monograph	Complies	YES
Assay	DAB Monograph (HPLC) EP 2.2.29	CBD total: \leq 1.0% CBN: \leq 1.0% THC total: 27 – 33%	< 0.1 % 0.1 % 28.7 %	YES
Foreign matter	DAB, EP 2.8.2	\leq 2.0 %	Complies	YES
Loss on drying	EP 2.2.32	\leq 10.0 %	7.6 %	YES
Pesticides	EP 2.8.13	Complies with the requirements EP 2.8.13	Complies*	YES
Aflatoxins	EP 2.8.18	B1: \leq 2.0 μ g/kg Sum B1, B2, G1, G2: \leq 4 μ g/kg	n.n. n.n.	YES
Heavy metals analysis	EP 2.4.27	Lead: \leq 5.0 ppm Mercury: \leq 0.1 ppm Cadmium: \leq 1.0 ppm	< 0.1 ppm* < 0.05 ppm* < 0.1 ppm*	YES
Microbiological purity		EP 5.1.8.C		YES
<i>TAMC</i>	EP 2.6.12	\leq 500 000 cfu/g	< 10 000 cfu/g	
<i>TYMC</i>		\leq 50 000 cfu/g	< 1 000 cfu/g	
<i>Bile tolerant gram neg. bacteria</i>	EP 2.6.31	\leq 10 000 cfu/g	< 100 cfu/g	
<i>Escherichia coli</i>		absent /1g	absent /g	
<i>Salmonella species</i>		absent /25g	absent /25g	

n.n. = below limit of quantitation (LOQ); LOQ Aflatoxin B1, B2, G1: 0.5 ppm; LOQ Aflatoxin G2: 1 ppm.

Examined by: QSI GmbH, Flughafendamm 9a, 28199 Bremen

*Eurofins BioPharma Product Testing Toronto, Canada

Expiry date	12/2024
--------------------	---------

I hereby declare that this batch of the medicinal product has been manufactured and tested in compliance with the applicable GMP regulations and in accordance with the master documents approved by the client and has been tested in compliance with recognized pharmaceutical regulations pursuant to § 6 No. 3 ApBetrO and is hereby released for marketing pursuant § 16 AMWHV.
All starting materials and intermediate products used have been tested and were approved.

25.07.2024



Dr. Klaus-Uwe Pechar

Date / Signature Qualified Person